Fig. 7.

Suppression of Raf1 expression by LCFA/MEDICA is proposed to be accounted for by activated AMPK, complemented by induced UPR. Raf1 suppression by AICAR is proposed to be solely accounted for by ZMP-activated AMPK. Suppression of Raf1 expression results in inhibition of the adenylate cyclase (AC) activity, followed by decrease in agonist-induced cAMP and in cAMP-induced PKA. Suppression of PKA-induced P-HSL and P-perilipin, followed by suppression of P-perlipin-induced CGI-58/ATGL, results in overall inhibition of agonist-induced lipolysis.